$695 | Single User
$1395 | Global License

Physician Views: Will next-generation long-acting insulins prove compelling?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 19 Nov 2014 | 172 | In Stock
Related Topics: Lantus , Lilly

Introduction

Scope



In the second of two diabetes-focused Physician Views polls being run by FirstWord Pharma PLUS this week (see also Physician Views: What opportunity for biosimilar basal insulin?), we are polling US and EU5-based endocrinologists to gauge their assessment of new long-acting insulins developed by Novo Nordisk (Tresiba), Sanofi (Toujeo) and Eli Lilly (Peglispro).


These newer products are poised to play a key role in how the multi-billion dollar basal insulin segment evolves over the next decade. They will dictate market share dynamics for their developers and should contribute to insulating the branded segment from loss of market share to biosimilar/generic versions of Sanofi's market-leading Lantus (expected to launch in the EU in 2015 and the US from 2016). This second issue appears particularly pertinent given the feedback we received earlier this week from endocrinologists, who appear very comfortable with the concept of prescribing biosimilar/generic Lantus (Physician Views Poll Results: What opportunity for biosimilar basal insulin?).


The significance of these newer products has also increased in light of Sanofi's recent disclosure that Lantus sales will be flat next year (due most likely to greater rebating with payers) and the potential leverage their availability will have on increased price compression in the market, alongside the subsequent launch of biosimilar/generic Lantus products. Concurrently, increasing efforts by payers to negotiate greater discounts could adversely impact the launch trajectories of these newer brands, argue some analysts, who cite only incremental improvement over currently available basal insulins.


Puchase Reasons


How these products are differentiated from Lantus and Novo Nordisk's marketed Levemir franchise, and how they are differentiated from each other is at the crux of forecasting their commercial outlook and the questions we are asking as part of this Physician Views poll. Specifically we are asking US and EU5-based endocrinologists...


  • Based on your knowledge of clinical data for newer long-acting insulins (Sanofi's Toujeo, Novo Nordisk's Tresiba and Eli Lilly's Peglispro), how would you describe the level of improvement these products broadly provide over currently-available therapies?

  • Overall, do you think these newer long-acting insulins demonstrate sufficient efficacy (i.e. hypoglycaemia) and convenience benefits (i.e. reduced daily dosing) to warrant premium pricing versus Sanofi's Lantus?

  • Which of these newer long-acting insulins do you think offers the most compelling improvement over existing therapies?

  • What is the primary factor for you selecting that product?

  • Returning to the key theme in Q1 (how would you describe the level of improvement these products broadly provide over currently available therapies), what 'bar to entry' do you broadly expect newer branded long-acting insulins to raise for biosimilar Lantus? (US respondents assume that biosimilar Lantus is NOT rated as interchangeable)
  • Table of Contents
    for Physician Views: Will next-generation long-acting insulins prove compelling?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    172 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Will next-generation long-acting insulins prove compelling? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...